| Breakdown | TTM | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.02B | 57.40B | 52.96B | 49.95B | 42.44B | 40.48B |
| Gross Profit | 41.82B | 40.47B | 37.82B | 36.39B | 33.56B | 32.62B |
| EBITDA | 27.00B | 23.91B | 21.39B | 18.74B | 13.53B | 18.41B |
| Net Income | 15.43B | 12.44B | 10.47B | 8.50B | 6.72B | 13.75B |
Balance Sheet | ||||||
| Total Assets | 204.98B | 168.36B | 140.98B | 134.38B | 109.30B | 131.11B |
| Cash, Cash Equivalents and Short-Term Investments | 19.77B | 11.20B | 10.66B | 10.19B | 21.90B | 46.55B |
| Total Debt | 124.39B | 104.10B | 94.47B | 90.48B | 75.86B | 84.25B |
| Total Liabilities | 174.53B | 147.39B | 131.74B | 132.83B | 115.06B | 125.16B |
| Stockholders Equity | 29.95B | 20.45B | 8.70B | 1.07B | -6.22B | 5.24B |
Cash Flow | ||||||
| Free Cash Flow | -13.18B | -394.00M | 11.81B | 8.47B | 5.03B | 13.75B |
| Operating Cash Flow | 22.30B | 20.82B | 18.67B | 17.16B | 9.54B | 15.89B |
| Investing Cash Flow | -31.59B | -21.71B | -7.36B | -36.48B | 11.22B | -13.10B |
| Financing Cash Flow | 17.44B | 1.10B | -10.55B | 7.91B | -29.13B | -10.38B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $2.89T | 24.34 | 34.39% | 0.71% | 16.67% | 28.60% | |
72 Outperform | $115.60B | 80.15 | 16.26% | ― | 15.30% | -60.71% | |
71 Outperform | $173.74B | 24.74 | 12.18% | 0.63% | 8.41% | 22.92% | |
69 Neutral | $223.33B | 27.70 | 16.64% | 1.07% | 11.85% | 167.23% | |
65 Neutral | $420.02B | 27.46 | 70.60% | 1.00% | 11.08% | 29.56% | |
62 Neutral | $88.30B | -287.57 | -8.88% | ― | 22.05% | -341.24% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% |
On February 2, 2026, Oracle entered into an equity distribution agreement with a syndicate of major investment banks to launch an at-the-market offering program allowing the company to sell up to $20 billion of its common stock from time to time, providing flexible access to equity capital while retaining the ability to suspend or terminate sales at its discretion. On February 4, 2026, Oracle completed the issuance of $25 billion in senior notes across multiple maturities and coupon structures, securing substantial long-term financing for general corporate purposes, including potential debt repayment, capital expenditures, acquisitions, and shareholder returns, in a move that significantly bolsters its funding capacity and financial flexibility.
The most recent analyst rating on (ORCL) stock is a Buy with a $205.00 price target. To see the full list of analyst forecasts on Oracle stock, see the ORCL Stock Forecast page.
On January 5, 2026, Oracle announced that George H. Conrades, 86, retired from its Board of Directors after 18 years of service, followed on January 7, 2026, by the retirement of Naomi O. Seligman, 87, after 20 years on the Board. The company stated that both long-serving directors stepped down effective immediately and that their departures were not due to any dispute or disagreement over Oracle’s operations, policies, or practices, signaling an orderly transition in board leadership rather than a response to internal conflict.
The most recent analyst rating on (ORCL) stock is a Hold with a $195.00 price target. To see the full list of analyst forecasts on Oracle stock, see the ORCL Stock Forecast page.
Oracle announced its fiscal 2026 Q2 financial results, reporting a significant increase in remaining performance obligations to $523 billion, up 438% year-over-year. The company’s total quarterly revenues rose by 14% in USD to $16.1 billion, driven by a 34% increase in cloud revenues. Oracle’s strategic shift towards chip neutrality and its focus on embedding AI across its software products are expected to enhance its market position, with its Multicloud database business experiencing rapid growth.
The most recent analyst rating on (ORCL) stock is a Hold with a $270.00 price target. To see the full list of analyst forecasts on Oracle stock, see the ORCL Stock Forecast page.
On November 18, 2025, Oracle Corporation’s Board of Directors elected Stephen Rusckowski as a director, expanding the board to 14 members. Rusckowski, with a rich background in healthcare and technology, is expected to provide valuable insights into Oracle Health’s operations. Additionally, Oracle held its 2025 Annual Meeting of Stockholders where directors were elected, executive compensation was approved, and Ernst & Young LLP was ratified as the independent accounting firm for the fiscal year ending May 31, 2026.
The most recent analyst rating on (ORCL) stock is a Hold with a $261.00 price target. To see the full list of analyst forecasts on Oracle stock, see the ORCL Stock Forecast page.